title: Testicular Cancer, Version 2.2015.
abstract: Germ cell tumors (GCTs) account for 95% of testicular cancers. Testicular GCTs constitute the most common solid tumor in men between the ages of 20 and 34 years, and the incidence of testicular GCTs has been increasing in the past 2 decades. Testicular GCTs are classified into 2 broad groups--pure seminoma and nonseminoma--which are treated differently. Pure seminomas, unlike nonseminomas, are more likely to be localized to the testis at presentation. Nonseminoma is the more clinically aggressive tumor associated with elevated serum concentrations of alphafetoprotein (AFP). The diagnosis of a seminoma is restricted to pure seminoma histology and a normal serum concentration of AFP. When both seminoma and elements of a nonseminoma are present, management follows that for a nonseminoma. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Testicular Cancer outline the diagnosis, workup, risk assessment, treatment, and follow-up schedules for patients with both pure seminoma and nonseminoma.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Motzer
authors.forename: Eric
authors.initials: E
authors.lastname: Jonasch
authors.forename: Neeraj
authors.initials: N
authors.lastname: Agarwal
authors.forename: Clair
authors.initials: C
authors.lastname: Beard
authors.forename: Sam
authors.initials: S
authors.lastname: Bhayani
authors.forename: Graeme B
authors.initials: GB
authors.lastname: Bolger
authors.forename: Sam S
authors.initials: SS
authors.lastname: Chang
authors.forename: Toni K
authors.initials: TK
authors.lastname: Choueiri
authors.forename: Brian A
authors.initials: BA
authors.lastname: Costello
authors.forename: Ithaar H
authors.initials: IH
authors.lastname: Derweesh
authors.forename: Shilpa
authors.initials: S
authors.lastname: Gupta
authors.forename: Steven L
authors.initials: SL
authors.lastname: Hancock
authors.forename: Jenny J
authors.initials: JJ
authors.lastname: Kim
authors.forename: Timothy M
authors.initials: TM
authors.lastname: Kuzel
authors.forename: Elaine T
authors.initials: ET
authors.lastname: Lam
authors.forename: Clayton
authors.initials: C
authors.lastname: Lau
authors.forename: Ellis G
authors.initials: EG
authors.lastname: Levine
authors.forename: Daniel W
authors.initials: DW
authors.lastname: Lin
authors.forename: M Dror
authors.initials: MD
authors.lastname: Michaelson
authors.forename: Thomas
authors.initials: T
authors.lastname: Olencki
authors.forename: Roberto
authors.initials: R
authors.lastname: Pili
authors.forename: Elizabeth R
authors.initials: ER
authors.lastname: Plimack
authors.forename: Edward N
authors.initials: EN
authors.lastname: Rampersaud
authors.forename: Bruce G
authors.initials: BG
authors.lastname: Redman
authors.forename: Charles J
authors.initials: CJ
authors.lastname: Ryan
authors.forename: Joel
authors.initials: J
authors.lastname: Sheinfeld
authors.forename: Brian
authors.initials: B
authors.lastname: Shuch
authors.forename: Kanishka
authors.initials: K
authors.lastname: Sircar
authors.forename: Brad
authors.initials: B
authors.lastname: Somer
authors.forename: Richard B
authors.initials: RB
authors.lastname: Wilder
authors.forename: Mary
authors.initials: M
authors.lastname: Dwyer
authors.forename: Rashmi
authors.initials: R
authors.lastname: Kumar
mesh_terms: D003131:Combined Modality Therapy; D019468:Disease Management; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D017410:Practice Guidelines as Topic; D018239:Seminoma / Q000175:diagnosis / Q000628:therapy*; D013736:Testicular Neoplasms / Q000175:diagnosis / Q000628:therapy*